The clinical utility of gene expression assays in breast cancer patients with 0–3 involved lymph nodes

Mali Barbi; Della Makower; Joseph A. Sparano

doi:10.1177/17588359211038467

The clinical utility of gene expression assays in breast cancer patients with 0–3 involved lymph nodes

Mali Barbi, Della Makower, Joseph A. Sparano

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Abstract

Multigene expression assays are prognostic for recurrence in hormone-receptor positive 2 (HER-2) negative breast cancer, and, in some cases, predictive of benefit from chemotherapy or extended endocrine therapy. The results of these assays may be used to guide treatment recommendations for early HER-2 negative breast cancer. We review the results of trials establishing the clinical utility of several commercially available gene expression assays.

Original language	English (US)
Journal	Therapeutic Advances in Medical Oncology
Volume	13
DOIs	https://doi.org/10.1177/17588359211038467
State	Published - 2021
Externally published	Yes

Keywords

breast cancer
chemotherapy
gene expression profiling
hormone receptor-positive breast cancer
hormone therapy

ASJC Scopus subject areas

Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1177/17588359211038467

Cite this

@article{28cf1055ee0048619e7353de9153ce09,

title = "The clinical utility of gene expression assays in breast cancer patients with 0–3 involved lymph nodes",

abstract = "Multigene expression assays are prognostic for recurrence in hormone-receptor positive 2 (HER-2) negative breast cancer, and, in some cases, predictive of benefit from chemotherapy or extended endocrine therapy. The results of these assays may be used to guide treatment recommendations for early HER-2 negative breast cancer. We review the results of trials establishing the clinical utility of several commercially available gene expression assays.",

keywords = "breast cancer, chemotherapy, gene expression profiling, hormone receptor-positive breast cancer, hormone therapy",

author = "Mali Barbi and Della Makower and Sparano, {Joseph A.}",

note = "Publisher Copyright: {\textcopyright} The Author(s), 2021.",

year = "2021",

doi = "10.1177/17588359211038467",

language = "English (US)",

volume = "13",

journal = "Therapeutic Advances in Medical Oncology",

issn = "1758-8340",

publisher = "SAGE Publications Inc.",

}

TY - JOUR

T1 - The clinical utility of gene expression assays in breast cancer patients with 0–3 involved lymph nodes

AU - Barbi, Mali

AU - Makower, Della

AU - Sparano, Joseph A.

N1 - Publisher Copyright: © The Author(s), 2021.

PY - 2021

Y1 - 2021

N2 - Multigene expression assays are prognostic for recurrence in hormone-receptor positive 2 (HER-2) negative breast cancer, and, in some cases, predictive of benefit from chemotherapy or extended endocrine therapy. The results of these assays may be used to guide treatment recommendations for early HER-2 negative breast cancer. We review the results of trials establishing the clinical utility of several commercially available gene expression assays.

AB - Multigene expression assays are prognostic for recurrence in hormone-receptor positive 2 (HER-2) negative breast cancer, and, in some cases, predictive of benefit from chemotherapy or extended endocrine therapy. The results of these assays may be used to guide treatment recommendations for early HER-2 negative breast cancer. We review the results of trials establishing the clinical utility of several commercially available gene expression assays.

KW - breast cancer

KW - chemotherapy

KW - gene expression profiling

KW - hormone receptor-positive breast cancer

KW - hormone therapy

UR - http://www.scopus.com/inward/record.url?scp=85112458832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85112458832&partnerID=8YFLogxK

U2 - 10.1177/17588359211038467

DO - 10.1177/17588359211038467

M3 - Review article

AN - SCOPUS:85112458832

SN - 1758-8340

VL - 13

JO - Therapeutic Advances in Medical Oncology

JF - Therapeutic Advances in Medical Oncology

ER -

The clinical utility of gene expression assays in breast cancer patients with 0–3 involved lymph nodes

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this